Association between increased serum GP88 (progranulin) concentrations and prognosis in patients with malignant lymphomas

作者：Yamamoto Yasuko; Goto Naoe; Takemura Masao; Yamasuge Wakana; Yabe Kuniaki; Takami Tsuyoshi; Miyazaki Tatsuhiko; Takeuchi Tamotsu; Shiraki Makoto; Shimizu Masahito; Adachi Seiji; Saito Koshiro; Shibata Yuhei; Nakamura Nobuhiko; Hara Takeshi; Serrero Ginette; Saito Kuniaki; Tsurumi Hisashi^*

来源：Clinica Chimica Acta, 2017, 473: 139-146.

DOI：10.1016/j.cca.2017.07.024

• GP88
• Progranulin
• Lymphoid malignancies
• Prognosis, DLBCL

Background: GP88 (progranulin; PGRN) is a secreted 88 kDa glycosylated protein, with important functions, including inflammation and tumorigenesis. We assessed the significance of GP88 expression in survival outcomes of patients with malignant lymphoma (ML).
Methods: Serum samples from 254 previously untreated ML patients were examined to measure GP88 concentrations using a sandwich human GP88 ELISA kit. Immunohistochemical analyses were performed to examine GP88 tumor tissue expression.
Results: The median serum GP88 concentration of ML patients was 91.3 ng/ml, and was significantly higher than that of the control group (median, 57.7 ng/ml) (p < 0.0001). Association between GP88 serum concentrations and overall survival (OS) was examined in patients with diffuse large B cell lymphoma (DLBCL) who had been stratified based on their serum GP88 concentrations. Kaplan Meier survival analysis showed that patients with serum GP88 concentrations of <= 116 and > 116 ng/ml, had 5-y OS rates of 70% and 50%, respectively (p = 0.02). The immunohistochemical analyses of GP88 tumor expression revealed that DLBCL patients had lymphoma cells that were positive for GP88.
Conclusions: High serum GP88 concentrations are associated with poor prognosis in patients with DLBCL.

• 出版日期2017-10